Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
1.600
+0.100 (6.67%)
At close: Jan 27, 2026

Silence Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
205325672547715611
Market Cap Growth
-18.88%-51.64%22.71%-23.44%17.04%-
Enterprise Value
103152600448612549
Last Close Price
1.602.631.503.257.156.97
PS Ratio
7.927.5121.2325.2842.5381.67
PB Ratio
2.762.4230.5420.5861.9349.39
P/TBV Ratio
3.242.6157.6633.06580.25487.96
P/FCF Ratio
----96.09-
P/OCF Ratio
----77.58-
EV/Sales Ratio
3.973.5218.9720.6736.4073.34
EV/FCF Ratio
-1.41---82.24-
Debt / Equity Ratio
0.000.000.020.020.020.04
Debt / FCF Ratio
----0.03-
Asset Turnover
0.140.270.250.180.140.08
Quick Ratio
7.1610.364.154.035.412.78
Current Ratio
7.6911.144.624.415.692.99
Return on Equity (ROE)
-64.30%-58.08%-223.22%-273.06%-448.22%-217.21%
Return on Assets (ROA)
-23.40%-19.24%-26.32%-26.09%-31.44%-29.33%
Return on Capital Employed (ROCE)
-54.10%-26.70%-54.00%-49.70%-56.50%-51.30%
Earnings Yield
-31.56%-13.95%-8.07%-9.20%-7.46%-7.27%
FCF Yield
-35.49%-20.89%-7.37%-10.45%1.04%-2.52%
Buyback Yield / Dilution
-7.98%-24.69%-15.21%-8.58%-8.78%-8.85%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.